EUCTR2013-001089-40-BG进行中（未招募）1 期
An extension study to evaluate the sustainability of clinical benefits, safety and tolerability of secukinumab in patients with active Ankylosing Spondylitis
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 274
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients having completed the core study CAIN457F2305.
- •- Indication for treatment extension
- •Other protocol-defined inclusion criteria may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 261
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 13
排除标准
- •- History of hypersensitivity to secukinumab or to any drug of similar chemical classes.
- •- Use of any investigational drug other than secukinumab during the core study CAIN457F2305.
- •Other protocol-defined exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
1 期
3-year follow-up study of secukinumab treatment in patients with active Ankylosing SpondylitisEUCTR2013-001089-40-NLovartis Pharma Services AG300
已完成
3 期
An extension study to evaluate the sustainability of clinical benefits, safety and tolerability of secukinumab in patients with active Ankylosing Spondylitis (CAIN457F2305E1)ankylosing spondylitis10023213NL-OMON44667ovartis9
进行中（未招募）
1 期
3-year follow-up study of secukinumab treatment in patients with active Ankylosing SpondylitisAnkylosing spondylitisMedDRA version: 19.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-001089-40-GBovartis Pharma Services AG300
进行中（未招募）
1 期
3-year follow-up study of secukinumab treatment in patients with active Ankylosing SpondylitisAnkylosing spondylitisMedDRA version: 20.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-001089-40-DEovartis Pharma Services AG274
进行中（未招募）
1 期
3-year follow-up study of secukinumab treatment in patients with active Ankylosing SpondylitisAnkylosing spondylitisMedDRA version: 18.1Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-001089-40-BEovartis Pharma Services AG300